Evotec

Founded 1993
Founders Charles Weissmann Freimut Leidenberger Heinrich M. Schulte Karsten Henco Manfred Eigen Rudolf Rigler Ulrich Aldag

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 17
Average round size
info
The average size of a deal this fund participated in
$45M
Portfolio companies 15
Rounds per year 0.61
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Artificial Intelligence
Summary

In 1993 was created Evotec, which is appeared as Corporate Investor. The leading representative office of defined Corporate Investor is situated in the Hamburg. The company was established in Europe in Germany.

Deals in the range of 10 - 50 millions dollars are the general things for fund. The top activity for fund was in 2019. The fund is constantly included in 2-6 deals per year. Speaking about the real fund results, this Corporate Investor is 6 percentage points less often commits exit comparing to other organizations.

The typical case for the fund is to invest in rounds with 3-4 participants. Despite the Evotec, startups are often financed by Tech Coast Angels, Frontier IP Group plc, CARB-X. The meaningful sponsors for the fund in investment in the same round are Alexandria Venture, venBio Partners, Woodford Investment Management. In the next rounds fund is usually obtained by GT Healthcare Capital Partners, Celgene, CARB-X.

This organization was formed by Manfred Eigen.

For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. We can highlight the next thriving fund investment areas, such as Health Care, Artificial Intelligence. The fund has no exact preference in some founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Carrick Therapeutics, Eternygen, Forge Therapeutics

Read more

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Wedo Capital China, Wenzhou
Longwater Investment China, Shanghai
Silver Cloud Ventures Ltd. United Kingdom, London
BeiChen Venture Capital Management China, Baoshan
Intelectium Ventures Spain, Madrid
Xin Yu Li Mei -
WHG Capital -
Studio Hyperset United States, Fremont
NITI AAYOG -
7RIDGE -

Notable deals

CompanyIndustryRoundRound SizeDateInvestorsLocation

Topas Therapeutics

Advanced Materials
Biotechnology
Chemical
Chemical Engineering
1
$21M29 Jul 2021 Germany, " Germany"}

OxVax

Biotechnology
Therapeutics
1
21 Apr 2021 United Kingdom, Oxford

Exscientia

Artificial Intelligence
Biotechnology
Health Care
Pharmaceutical
1
$40M04 Mar 2021 United Kingdom, Oxford

ARGOBIO

Biotechnology
n/a
$59M02 Mar 2021 France, Paris

Blacksmith Medicines

Biotechnology
Genetics
Life Science
1
08 Jan 2021 United States, San Diego

Autobahn Labs

Biotechnology
Life Science
Therapeutics
1
24 Jun 2020 United States, Palo Alto

Exscientia

Artificial Intelligence
Biotechnology
Health Care
Pharmaceutical
1
$60M26 May 2020 United Kingdom, Oxford

Immunitas Therapeutics

Biotechnology
Life Science
Therapeutics
1
$39M22 Nov 2019 United States, Cambridge

Aeovian Pharmaceuticals

Biopharma
Biotechnology
Health Care
Pharmaceutical
1
$37M03 Oct 2019 United States, San Francisco
News
Immunitas Therapeutics Closes $58M in Series B Financing

– Immunitas Therapeutics, a Waltham, MA-based single cell genomics-based therapeutics company, closed a $58m Series B financing.
– The round was led by Agent Capital with participation from Medical Excellence Capital (MEC), 120 Capital, Solasta Ventures, Mirae Asset, Ono Venture Investment, The Mark Foundation for Cancer Research, NS Investment, BrightEdge (American Cancer Society), and The Leukemia & Lymphoma Society . Existing investors Alexandria Venture Investments, Evotec, Leaps by Bayer, M Ventures, Novartis Venture Fund (NVF), and founding investor Longwood Fund also joined the round.
– The company intends to use the funds to advance its lead program, IMT-009, a CD161 inhibitor, into the clinic to treat both solid tumors and hematological malignancies.

Exscientia Closes $100M in Series C Financing

– Exscientia is a clinical stage pharmatech company pioneering the use of artificial intelligence (AI) to design new drugs.
– Company raised 100m in Series C funding.
– The round was led by BlackRock with participation from Novo Holdings, Evotec, Bristol Myers Squibb, and GT Healthcare Capital.
– The company intends to use the funds for platform development towards autonomous drug design, extension of its proprietary pipeline into clinical trials and expansion of existing capabilities in biological analytics that support target selection and portfolio development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Evotec?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Crunchbase icon

Content report

The following text will be sent to our editors: